MC1R and endothelial dysfunction: A synthetic MC1R agonist (BMS-470539), for instance, was demonstrated to inhibit leucocyte trafficking in the inflamed vasculature [52], and the natural agonist α-melanocyte-stimulating hormone was shown to regulate vascular NO availability and to protect against endothelial dysfunction [53].